biogen i think will do really well. they have a label update coming up soon, december 4th and after that, all-cleared by that stock. >> lilly still not cheap. it's been tough sledding for this stock for a long time. not like lilly was making 52-week highs and fell off the cliff today. it's been now a year, year-and-a-half since lilly made its all-time high. valuation to me is still expensive. alzheimer's is a huge deal. it was a huge deal for them. and this phase three miss is clearly not good. the one thing you can take away, it traded about ten times normal volume, which maybe have a short-term bottom but there are not a lot of catalysts going forward but i still think the trajectory is lower. >> i think you have to measure what this means in terms of relevant earnings and the streets coming out, 5 to 15% right now in terms of the impact of this. so you can throw that on this valuation. and you can make an argument that this stock was overdone. you've -- and the problem is, the charters can probably say this is no man

mark: what does it mean for biogen? it is close behind eli lilly.s true that the biogenic drug is more potent but has more side effects than the eli lilly drug. the problem is we do not know why it did not work out. it is possible that not enough drug got into the brain. your for privileged organ that is protected from everything else. if it is because not enough got into the brains, it could affect the same thing for, same issue for biogen. potent, maybe they will overcome that. very difficult to turn. we safer those small drugs the company is developing. it is slightly different approach to attack the same molecular problem in the brain. vonnie: if i can turn to you, eli lilly has wrapped up a meeting. have you had a chance to listen to the call or see in of the headlines from the call, what is next for eli lilly in terms of the drug? will be to see the full data when it is presented next month at an alzheimer's meeting. inre is process understanding is that the use the drug in earlier patients. it is some work that is ongoing and assess whether t

the biogenic components of the weapons eddington's been using are very bulky and very unstable. they need to be kept and ififnyone knows how to keep things cold, it's the breen. thank you, odo. captain. mr. worf do we have a series of sensor relays near portas five? yes, sir. two class-five intelligigce drones. pull their sensor logs. i want to see who's been visiting the breen system. captain's log: supplemental. odo's huncnc has proven accurate. our intelligence drones detected a maquis freighter tering portas five three hours ago. the freighter was last seen headed into the dorvan sector of the d.m.z. considering the freighter's range, velocity and d ading eddington's next target is one of four cardassian colonies. but... these targets are unlikely. their defense systems were recently upgraded by the cardassians. hmm. at leaves only quatal and panora. quatal has a lucrative mining operation and their weapon systems arein the process of being upgraded targe but they're not fully operational. t. not as tempting as panora. the maquis attacked them two months ago. most of theiei

what i don't understand is where the maquis got the materials to make a biogenic weapon. i do. the selenium and the rhodium nitrite they hijacked can be reformulated and with some work synthesized to produce... cobalt diselenide. where's themalinche? they're headed for veloz prime but by the time they get there... eddington will be long gone. given the amount of chemical compounds eddington stole how many of these weapons will he e able to make? enough to poison every cardassian colony in the d.m.z. there must something we can do. worf, are they any other starships near veloz prime? themalincheis our only ship? in the sector. so unless they stop eddington the maquis have turned the tide. there is another ship in the area. defiant. - [narrator] what if you had a medical emergency away from m me? - my chest hurts, i can't breathe. - [narrator] what you need is mobilehelp, but with mobilehelp, you get help outside the home with coverage nationwide on one of the largest cellular networks at the press of a button. - i couldn't dial 911 because i was out of it. i just pushed the butt

. >>> biotech companies eye onus and biogen said their experimental drug for treating spinal muscularophy showed promise. the company said the children given the treatment showed a statistically significant improvement in motor function compared to those who didn't receive the medication. eye onus shares surged as much as 18% to $32.12. shares of biogen popped. >>> and lower raw milk prices helped dean foods post earnings that surpassed analysts' expectations. the nation's largest dairy processor said it saw volume performance improve and expects that trend to continue. shares were up 42 cents to $18.88. travel booking company priceline said an increase in hotel bookings helped to lift its revenue. net income did see a decline as a more than $900 million charge tied to the company's open table business ate into profits. even so, those results still exceeded street targets. shares rose in after hours trading but ended the regular day up to $1,480.33. >>> major oil hub in oklahoma was rattled overnight by an earthquake. a magnitude 5.0 quake shattered windows and caused substantial dama

we're talking juno, lily, biogen and more. is this a great time to jump in?> also coming up a great pick from one of our halftime traders is mowing down the bears? "the halftime report" with scott wapner is back in two minutes. alpha seems more elusive today. is it because so many go after it the same way? chasing after short term returns. instead if getting caught up with the crowd, the investment managers at pgim take a long term view, teaming specialized active investing with risk-management rigor, to seek out global opportunities. we manage over a trillion dollars this way, attracting many of the world's leading investors. partner with pgim. the global investment management businesses of prudential >> health care taking a hit. eli lily announcing its alzheimer's drug failed in a late stage trial. doc, you bought lily. >> bought lily. i bought it, judge, typical doc fashion. talking about myself. >> what is it called again? >> brian, i mean, this is what you did with wells. this one had the blood. the blood in the streets on the alzheimer's drug, we wish t

>> i think by far and away investors will look to biogen biogen has drug, in several phase three programsntly it is without getting too much into weeds on the science it binds clusters of data amyloid as opposed to single proiven lilike lilly the exciting mechanisms of action on alzheimer's a mechanism a base inhibitor inhibits production or looks at alzheimer's a lot of innovation to come clearly this was the latest stage was thank you know, most out there. >> jeff other than biogen are there other public companies to watch that are involved in development here? >> merck only other one in later stage biogen's partner, as well, but merck base inhibitor could have data in the sick half of next year, beyond that there are a couple smaller companies in the biotech, alzion one biotech space for the most part phrma large a couple biotechs, the bigger players. >> plunging this morning is in warranted do you think this is right reaction? >> i think clearly there is from a incent perspective the stock should be down, i wouldn't be surprised to see lilly rebound a little bit because, you know ther

especially for biogen, biogen down 5% or so, this morning i thought the results should be higher, thetock should be higher today. most of what happened in mai view is the elimination of potential competitor from lilly, and now their drug still has the same odds of success made slightly higher because of the trend that was efficacy that lilly showed and in general believed the biogen drug is better and therefore i think the stock is worth more today than yesterday. >> okay. thank you so much. we appreciate it. >> thank you. >> to the trump rally we go. the dow and the russell 2000 small cap index hitting new highs. dom chu with the stocks that are pushing this market higher. >> another day, another record for the dow jones industrial average, now solidly above the 19,000 mark. we'll see what the 38 point gain today. i want to call your attention to the bigger point gainers driving things. if you look here, post 5, citadel securities post, you see goldman sachs up by half a percent, but carries a lot of weight in the dow. one of the biggest point contributors to today's move higher for

want to show you shares of biogen. while there may be more trouble ahead, evaluation seems like a reasonable entry. the firm goes to overweight. what do we think? they're taking a shot here. they are saying, we hope we don't regret it. >> part of the thesis appears to be alzheimer's research, which is notoriously tricky. a lot of companies have failed to make any progress. they may be wrong in that regard. where they are right is that the valuation is very cheap. that gives them a margin of safety. >> alzheimer's has a chance, maybe. the company dropped the ball but maybe they can pick it up. as i characterized it, you are talking about a big day for biotech, best since april. where does this stock fit in? >> if you are a trader, you are not on this thing. basically, the stock was able to run right back into its declining 50 day. that's where the advance was halted. that's not an accident. price has memory. you have got this big gap overhead. that's going to be tough to get through. however, if you are an investor, you

biogen falling as well. eli lilly down 15%.cut you down to a cash open in new york. all four equity markets in this country at all time highs. this is bloomberg. ♪ guy: one big stock on the move -- eli lilly says it's attempt to find a drug to treat alzheimer's has failed in final testing. the company punching in the premarket. on the story,re jewel armstrong, he leads our team reporting on u.s. health care. a huge blow for many of the people waiting to see if we would finally see a therapy that would treat alzheimer's. give assistance of the size and scale of what we are looking at here. drew: this is a massive disappointment for investors and patients here. they were further along than just about any other company out there in a serious trial of alzheimer's disease therapy that was attempting to actually stop the course of the disease, or slow the course of the disease. they had designed the trial after two large, expensive trials, and failed earlier. they may do this thing so that if there was any signal the drug was going t

drug company biogen, down 1%, and google parent company, alphabet, which is pretty much flat for theear. so a big question is how many of these companies can turn things around and get that spark to move them in the right direction? in the meantime, maybe think about talking more stocks at the thanksgiving dinner table and less about politics. gobble, gobble. for "nightly business report," i'm dominic chu here at the new york stokes. >> gobble, gobble indeed. >>> fed policymakers appear ready to do something they haven't done in about a year. raise interest rates. hampton pearson device into the minutes of the central banks' last meeting. >> just-released minutes show monetary policymakers moving closer to raising key short term interest rates for the first time in nearly a year. with some even suggesting if they didn't raise rates in december, there was the risk of losing credibility, given audioloall the signals about an impending hike. >> they're shifting the goalpost for i think the investing public to begin to concentrate on what signals we'll get in december at the press confer

you intend to detonate a biogenic charge in earth's atmosphere. it would infect all life-forms with nanoprobe viruses. dual. by the time they realized what was happening half their population would be drones. inefficient. the virus would take years to proliferate. we've waited this long. interface with the central alcove. begin programming the nanoprobes. be sure to enhance the viral sequencers. this is no different. to you, perhaps. part of me is still human. i will not assist in their destruction. we all originated from lesser species. i myself came from species 1-2-5 but that's irrelevant now. we are borg. i am an individual. you're only repeating their words. you sound like a mindless automaton. comply or we will turn you into a drone. proceed if you wish. you're torn between your desire to be one with us and your loyalty to them. it's time for you to complete your task. remorse, compassion will be irrelevant once humanity is assimilated. forgetvoyager. they were never your collective. i am annika hansen, human. i remember annika. does she rem

also take a look at shares of biogen. different approach, but it's getting hurt as well.iogen of course also has a drug for alzheimer's underway. and that stock down about 6%. this has been, you know, i can remember a number of weeks back it was bristol-myers got crushed when unexpectedly that was nonsmall cell lung cancer there, i believe the drug there, but this is always key risk for people who are investors in this sector and it's big seeing with that 15% loss. >> a lot of analysts saying this was the key catalyst for q-4. not like lilly doesn't have any drugs which the executives this morning were sure to make that point. but there was this article in "the wall street journal" the day before that there was a lot riding on this because so many previous alzheimer's treatments that would stop or halt the disease had failed. this 2014 study by the cleveland clinic researchers found 99.6% out of more than 400 alzheimer's trial failed over a ten-year period. so just disappointing from a society perspective. but meg did ask executives this morning whether they were still co

biogen and silky recovering. -- celgene recovering. 65% of s&p 500 companies have reported their third-quarters and 76% beaten estimates. with barely the average gain shy of 1/10 of 1%, it is a typical quarter. our next guest says the economies are at a major pivot point. joining me is chris hyzy. what is the pivot point? chris: there is quite a few, but the biggest is switching from a deflation world into a wage pressure world. is that transition happens you are going to see the move from high-quality dividend producing, dividendelding u.s. outperformance to a cyclical value. banks,l's, technology, emerging markets. that tipping point starting to get picked up in earnings around the world. vonnie: is that what your clients are most worried about? or are they more worried about the election? you manage some wealthy people. i want viewers to have a look at the chart. expectationsation for the 10 year yields are moving up as it looks like there might be a clinton presidency. when the e-mail controversy reignited it is lower. chris: we have all of this underneath sea level, all of this earnings d

this happened with biogen too. so many drug companies have failed trying to fight alzheimer's that it's way too arrogant to bet that you're on the right path with any one company's research department. so here's the bottom line. when you're going to invest in a company with a potential cure for an intractable illness, make sure the drug company you're investing in has multiple drugs away from it in the pipeline and a good balance sheet as well as a dividend to protect the down side. second, if the drug doesn't initially work but it hasn't been written off, expect a bounce. a better time to sell. third, don't buy the stock when it's still a ton of hoopla out there about its new drug. wait until the fuss dies down and get a better price for the stock. finally, when you have a drug company against a dwult disease that many others have failed to cure, please be more skeptical. there is a reason that others fail. it's an incredibly problem to solve. the company you like might fail too. investing in biotech can be a chal

. >>> and why one firm upgraded biogen, who say they hope they don't forget the move. will they? we'll see you in about 20 minutes. >> thanks, scott. not just the broader markets, some key names are also watching, shares of oracle are moving higher, the company is now set to close that netsuite deal with more than 50% of the shares that are not controlled by larry ellison. it had been in question, t. rowe price was in question whether they -- how hard they'd fight this deal, but now regardless it appears oracle has gotten netsuite, that gives them a new tool in the cloud when it comes to trying to capture some of that mid market market share that they've talking about targeting with this deal, and, of course, larry ellison did have a big stake in the suite, having helped to start it, but those shares were not counted toward how this eventual deal would turn out. >> was it always thought to be a given, considering ellison held those shares? >> it was at first, but then they had trouble actually getting all the shares to vote out. it looked perhaps too sweet a deal for oracle. t. r

are being forgiven for missing key end points and important clinical trials while still others like biogen and eli lilly are being given the benefit of the doubt for their pipelines, both of which include possible alzheimer's cures, however hard stocks. i read multiple obituaries of these great growth companies as money managers sold their stocks in order to raise money so they could buy the banks, the industrials, and the drug stocks. it was a robbing peter to pay paul scenario because no new money was coming into the market initially. but that was phase one of the trump rally. but guess what? phase two is back. phase two means that fang is back. it feels like this time there must be new money coming in to back up the move in phase two. let's take them one at a time. first there's facebook, which has acted like face plant on the canvas ever since it reported a few weeks ago, plummeting from 133 before the quarter down to 115 last week. then after the bell friday, the company announced a $6 billion buyback along with the resignation of its chief accounting officer. now, how negative were p

you have celgene and biogen. these are stocks that are accumulated while the rest of the sector are being sold off. these are the ones that involve the most if and when this sector finds momentum. >> yeah. i just like to enter bristol-myers stock. came way down. over done because of a drug trial that i think they blew. great franchise in cancer. larger multiple. that's very attractive. >> tiffany is having its best day in more than a year today after a surprise earnings beat. is the high-end consumer back in the game, and how do you play that? plus, bullish call on duncan. a healthy outlook for a big health care name. our blitz is just ahead as well. ♪ if you're on medicare, remember, the open enrollment period is here. the time to choose your medicare coverage begins october 15th and ends december 7th. so call unitedhealthcare to enroll... in a plan that could give you the benefits and stability you're looking for, an aarp medicarecomplete plan insured through unitedhealthcare. what makes it complete? it can com

biogens the brown--but against the browns they have won 10-12. and they are favored by eight points and they are bringing big ben roethlisberger to town. and when you look at the browns, it is the quarterback situation that continues to be the problem. flacco owns the browns, so does ben roethlisberger. 9-2 in his career death and the browns just have not had a quarterback. and how cody is going to face big ben. he is 0-7 as a starter. throwing down the field as been a folk on him. it is time to take more chances. --has been a knock on him. it is time to take more chances. >> yes, obviously, as a quarterback, you want to be able the extend drives but be smart with the noble and keep happen--with the tool, and keep it. --with the football, and keep it. you know, you have to find a happy medium. >>> all right, college football. you know, michigan stated has ruined a couple of--state has ruined a couple of buck eye seasons in the past. but they were not able to get it done and the buck eyes get the win. the weather was a huge factor yesterday, it wa

president-elect donald trump firing back.ing back >> reporter: good morning.rnin this effort is being led biogen -- candidate jill stein.atill stei. looking at pennsylvaniaing a michigan and wisconsin where state officials are gatheringcos today to discuss how to move hoe forward now with a recount. a ru donald trump emerged from his mar-a-lago home in floridago h getting ready to head back to new york and a growing battletl over the election that madet m him president-elect. >> it's been so exciting tm opr see people mobilize around the t vision of this recount recnt campaign. >> reporter: green partyorte grp candidate jill stein heading states so far joining her arere representatives from hillary clinton's campaign. camign. that drew fire from trump whoro responded on twitter with anithn allegation of his own. serious voter fraud infraud virginia, new hampshire and california.fo so why isn'trn the media reporting on this? seriousus bias.bias big problem. probl and his incoming chief ofhief staff did not hide hisot hide hi frustration. >> it is a total and complete hypocritical joke that theic

you have biogen, like one of the big health care stocks that are up, as well in the biotech area, pharmaceuticals, like abbott and bristle myers are all up. people are saying why is this happening if hillary might become more likely to become president. divided government, house stays republican, likes it much more likely she'll be able to have a deleterious effect on the sector. everyone will have coverage, all flying today. community health, hca, universal health, all on the upside. finally, rates are still moving up. dollar is strong, rates are higher here today. and we got a number of financial stocks at new highs. new high list is not big, but prudential, regions, key corp., sitting at 52 week highs. back to you. >> bob, thank you very much. let's dig in on why we're seeing a rally today. the fbi saying it sees no reason in that second batch of e-mails to charge hillary clinton. eamon javers in washington with the latest. >> that's right. let me share with you the sentence from the letter that the fbi director sent to capitol hill yesterday that got the markets attention. he said, based on o

most specifically biogen, which has a similar drug in late-stage studies.esult here, guys. >> meg, carter had a question. >> from what i understand, the logistics of administering this drug are complicated. do you know if lilly's -- it has some kind of a contingency plan for if the drug does get approved, how it is going to explain that to regulators and get to market? >> that's a huge part of it here. this is not a pill, a drug that would be infused so there is a system with working with infusii infusion centers. we talked with dave ricks and they say they are talking to payers about potentially reimbursing for this and figuring out that system. not just of administering the drug, but also testing patients to make sure they have the buildups in their brains which make them eligible for the drug. >> thank you for joining us. meg tirrell. >>> the markets closed at record highs. can the momentum push forward into tomorrow? what to watch for, right after this. isn't major medical enough? no! who's gonna' help cover the holes in their plans? aflac! like rising

questioned whether the drugs are directly comparable and whether this does have implications for biogentreatment. those shares are down 4%. kite pharma developing a similar cancel treatment to that of juvenile therapeutics. they are still getting caught in that downdraft. in theu take a step back pause we are seeing, it is heading back to an overbought level. on thesee the red line top of the green line on the bottom, we have seen stocks get oversold and early november. they nearly got to overbought at least again on this indicator before we saw this little bit of a pullback. we are also seeing rates closely pull today. the two year yield now at the highest going back to 2010. this is a one-month move that we have seen, a huge move in these areas. up 30 year yield has gone two basis points. mortgage rate that has climbed considerably now at 3.95%. we've also been watching commodities particularly in the metals. divergencediversio between industrial metals. metal, and led have been rising. there optimism over potential infrastructure spending under the trump administration. ande are vari

one of the best performing stocks on the s&p today is biogen. it's gaining after the company said that their drug helped a wider group of patients with a deadly muscle disease in a late stage study. it showed success in a smaller group of patients, now a wider group. stocks from both companies are rising. iona, up 20%. there are indications from the election. we are seeing the hospital related specialty care providers up today in universal health services. benefiting from continual care act subsidies, lcs financial credit suites making comments to that effect. you don't only want to watch these today. watch them tomorrow, wednesday, and going forward based on what could happen with the aca. health care shares rallying, volatility coming down to some extent. this is a spread between my -- between one month implied volatility. spiking on friday since its highest -- to its highest since the u.k. vote for brexit. coming down to some extent today, seeing a few of these hedges being taken down off the market. we are seeing a broad stock rally, with ri

biogen has a drug that targets these plaxico burress and target them in different ways.s why it's important to see -- >> it's an anti-body that's very specific if you copy millions of it goes in the text. >> i see it on these new drugs these days. >> there's a lot of them. they are more expensive. how do we treat -- if this works how do we change the paradigm to treat folks with alzheimer's in early stages and get screened for it. we're talk about lumbar punctures to see if you have plaques in your spinal fluid. >> i had no idea. i thought it was up in your brain. they are in your bloodstream. >> they are hoping by clearing from the blood and that little bit that crosses the blood brain barrier will help. >> the other thing, they've done all phase one and two. so it's safe. whenever you use these things, the response is still mouse or fully humanized? >> i have to check on that. so far it looks safe. big side effect we've started to see in these trials is edema, fluid in the brain. we haven't seen that so much with lilly's drug. other thing is looking for infusion reacti